anti mers 3a1 mab

Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human monoclonal IgG1 antibody derived from CHO cells. It effectively inhibits the interaction between the MERS-CoV spike protein and the DPP4 receptor[1].

RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.

Anti-Mouse H-2K Antibody is an IgG2b isotype inhibitor targeting the mouse H-2K antigen, sourced from a murine host.

Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12), a human monoclonal IgG1, specifically targets the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD). By directly binding to this region, it effectively neutralizes the virus by blocking its ability to bind to receptors [1].

Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody, is expressed in CHO cells. It effectively competes with the virus Spike protein for binding to the CD26 receptor, consequently inhibiting viral invasion into host cells.

Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach for SARS-CoV-2 treatment[1]. [1]. Chunyan Wang, et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nat Commun. 2020 May 4;11(1):2251.

The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the SARS-CoV-2 RBD. [1]

Anti-SARS-80R mAb (SARS-80R) is a human IgG1 monoclonal antibody that is derived from CHO cells. Its main function is to selectively bind to the Spike (S1) protein, effectively preventing the infection of susceptible cells by the SARS virus[1].

Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody derived from CHO cells. It specifically targets the S1 domain of the Spike protein in both SARS-CoV and SARS-CoV-2.

Anti-Mouse LAG-3 is a rat-derived IgG1 antibody inhibitor targeting mouse LAG-3.

Spartalizumab (anti-PD-1) is a useful organic compound for research related to life sciences and the catalog number is T35396.

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.